Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG003 for neovascular age-related macular degeneration
2006-006358-86Phase 2Terminated
- Sponsor
- CoMentis, Inc.
- Start
- Mar 2007
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of antilymphocyte serum in exudative macular degeneration and age-related macular degeneration (AMD) (3 arms), sponsored by CoMentis, Inc. Primary endpoint: Primary efficacy endpoint. Started Mar 2007; status: terminated.
02
Drugs
antilymphocyte serum
03
Conditions
exudative macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2006-006358-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006358-86.